{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:12:06Z","timestamp":1783537926843,"version":"3.55.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00628","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T10:25:18Z","timestamp":1587119118000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment"],"prefix":"10.3389","volume":"11","author":[{"given":"Claudia","family":"Bettoni da Cunha-Riehm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Hildebrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Nathrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"key":"B1","first-page":"p. 46","article-title":"Cancer incidence and survival among children and adolescents: united states SEER program 1975-1995","author":"Ries","year":"1999","journal-title":"SEER Program."},{"key":"B2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid leukemia: reminiscences and dreams.","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematologica."},{"key":"B3","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML.","volume":"112","author":"Druker","year":"2008","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/bjh.12977","article-title":"International BFM group (iBFM) study group chronic myeloid leukaemia committee. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.","volume":"167","author":"de la Fuente","year":"2014","journal-title":"Br J Haematol."},{"key":"B5","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood.2018882233","article-title":"How I treat chronic myeloid leukemia in children and adolescents.","volume":"133","author":"Hijiya","year":"2019","journal-title":"Blood."},{"key":"B6","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol."},{"key":"B7","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia."},{"key":"B8","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population.","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Intergroupe Fran\u00e7ais des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"EURO-SKI investigators. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"B11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112905","article-title":"Features and outcome of chronic myeloid leukemia at very young age \u2013 data from the international pediatric CML registry (I-CML-Ped Study).","author":"Meral G\u00fcnes","year":"2018","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia.","volume":"50","author":"Millot","year":"2014","journal-title":"Eur J Cancer."},{"key":"B14","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/pbc.26028","article-title":"Recognizing Endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia.","volume":"63","author":"Samis","year":"2016","journal-title":"Pediatr Blood Cancer."},{"key":"B15","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/bjh.15826","article-title":"Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study.","volume":"185","author":"de Bruijn","year":"2019","journal-title":"Br J Haematol."},{"key":"B16","first-page":"976","article-title":"Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.","volume":"9","author":"Mattiuzzi","year":"2003","journal-title":"Clin Cancer Res."},{"key":"B17","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood."},{"key":"B18","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2006-04-018705","article-title":"Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.","volume":"108","author":"Mumprecht","year":"2006","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14639230500236818","article-title":"Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.","author":"Ikeda","year":"2006","journal-title":"Leuk Lymphom"},{"key":"B20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S1473-3099(16)00118-3","article-title":"ECIL-5. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).","volume":"16","author":"Mallet","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"B21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","article-title":"Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.","volume":"122","author":"de Lavallade","year":"2013","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.exphem.2008.09.013","article-title":"Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.","volume":"37","author":"Fraser","year":"2009","journal-title":"Exp Hematol."},{"key":"B23","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","article-title":"Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.","volume":"39","author":"Sillaber","year":"2009","journal-title":"Eur J Clin Invest."},{"key":"B24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nm1265","article-title":"Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases.","volume":"11","author":"Reeves","year":"2005","journal-title":"Nat Med."},{"key":"B25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1128\/JVI.01814-10","article-title":"Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases.","volume":"85","author":"Reeves","year":"2011","journal-title":"J Virol."},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27368","article-title":"Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: a report from the japanese pediatric leukemia\/lmphoma study group.","volume":"65","author":"Kurosawa","year":"2018","journal-title":"Pediatr Blood Cancer."},{"key":"B27","first-page":"S58","article-title":"Fragen und antworten zu verschiedenen impfungen, [Article in German].","volume":"8","year":"2001","journal-title":"Epidemiologisches Bulletin Nr."},{"key":"B28","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European leukemianet recommendations for the management of chronic myeloid leukemia: 2013.","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.49","article-title":"Measles.","volume":"2","author":"Rota","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMcp1905181","article-title":"Measles.","volume":"381","author":"Strebel","year":"2019","journal-title":"N Engl J Med."},{"key":"B31","first-page":"l","article-title":"Measles cases in Europe tripled from 2017 to 2018.","volume":"364","author":"Thornton","year":"2019","journal-title":"Br Med J."},{"key":"B32","year":"2019","journal-title":"Immunization, Vaccines and Biologicals: New Measles Surveillance Data For 2019."},{"key":"B33","year":"2019","journal-title":"Ten Threats to Global Health in 2019."},{"key":"B34","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.15585\/mmwr.mm6747a6","article-title":"Progress toward regional measles elimination \u2014 worldwide, 2000\u20132017.","volume":"67","author":"Dabbagh","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B35","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1056\/NEJMp1905099","article-title":"Measles in 2019 \u2014 going backward.","volume":"380","author":"Paules","year":"2019","journal-title":"N Engl J Med."},{"key":"B36","year":"2020"},{"key":"B37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5045\/br.2016.51.4.249","article-title":"Clinical characteristics and outcomes of varicella zoster virus infection in children with hematologic malignancies in the acyclovir era.","volume":"51","author":"Kim","year":"2016","journal-title":"Blood Res."},{"key":"B38","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/archpedi.1983.02140350057014","article-title":"Varicella in immunocompromised children. Incidence of abdominal pain and organ involvement.","volume":"137","author":"Morgan","year":"1983","journal-title":"Am J Dis Child."},{"key":"B39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/TP.0b013e31823aa528","article-title":"Morbimortality of pandemic influenza A H1N1 infection in kidney transplant recipients requiring hospitalization: a comparative analysis with nonimmunocompromised patients.","volume":"93","author":"Camargo","year":"2012","journal-title":"Transplantation."},{"key":"B40","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.4103\/0366-6999.206358","article-title":"Measles outbreak in pediatric hematology and oncology patients in Shanghai, 2015.","volume":"130","author":"Ge","year":"2017","journal-title":"Chin Med J (Engl)."},{"key":"B41","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.bbmt.2015.11.015","article-title":"Outcomes of influenza infections in hematopoietic cell transplant recipients. Application of an Immunodeficiency Scoring Index.","volume":"22","author":"Kmeid","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"B42","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3324\/haematol.2011.041913","article-title":"Infectious diseases working party, european group for blood and marrow transplantation; infectious complications subcommittee, spanish group of haematopoietic stem cell transplantation. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients.","volume":"96","author":"Ljungman","year":"2011","journal-title":"Haematologica."},{"key":"B43","first-page":"p. 649","article-title":"2018-2021 Red Book: report of the Committee on Infectious Diseases","author":"Manistarski","year":"2018","journal-title":"Lessons From an Outbreak of Varicella Infection in Pediatric Hemato-oncology Patients. Pediatric Infection Disese Journal."},{"key":"B44","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/adc.56.11.841","article-title":"Serious infections during continuing treatment of acute lymphoblastic leukaemia.","volume":"56","author":"Ninane","year":"1981","journal-title":"Arch Dis Child."},{"key":"B45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/INF.0b013e3182481ef8","article-title":"Characteristics and outcomes of pandemic 2009\/H1N1 versus seasonal influenza in children with cancer.","volume":"31","author":"Shah","year":"","journal-title":"Pediatr Infect Dis J."},{"key":"B46","first-page":"1","article-title":"Centers for disease control and prevention.prevention of measles, rubella, congenital rubella syndrome, and mumps: summary recommendations of the advisory committee on immunization practices (ACIP).","author":"McLean","year":"2013","journal-title":"MMWR Recomm Rep."},{"key":"B47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"Infectious diseases society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tax082","article-title":"Safety of live vaccines on immunosuppressive or immunomodulatory therapy-a retrospective study in three swiss travel Clinics.","volume":"25","author":"Huber","year":"2018","journal-title":"J Travel Med."},{"key":"B49","first-page":"353","article-title":"Hinweise zu Impfungen f\u00fcr Patienten mit Immundefizienz Stand: Sept. 2005. [Article in German].","volume":"30","year":"2005","journal-title":"Epidemiol Bull."},{"key":"B50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00508-016-1033-6","article-title":"[Guidelines for vaccination of immunocompromised individuals]. [Article in German].","author":"Wiedermann","year":"2016","journal-title":"Wien Klin Wochenschr."},{"key":"B51","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/MPG.0b013e3181bab351","article-title":"Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy.","volume":"50","author":"Lu","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B52","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.3748\/wjg.v23.i42.7644","article-title":"Vaccinations in immunosuppressive-dependent pediatric inflammatory bowel disease.","volume":"23","author":"Nguyen","year":"2017","journal-title":"World J Gastroenterol."},{"key":"B53","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/rheumatology\/kex189","article-title":"(Review) Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy.","volume":"57","author":"Cates","year":"2018","journal-title":"Rheumatology."},{"key":"B54","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/707691","article-title":"Guidelines on vaccinations in paediatric haematology and oncology patients.","volume":"2014","author":"Cesaro","year":"2014","journal-title":"Biomed Res Int."},{"key":"B55","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1080\/21645515.2017.1318236","article-title":"Safety and immunogenicity of Bio PoxTM, a live varicella vaccine (Oka strain) in Indian children: a comparative multicentric, randomized phase II\/III clinical trial.","volume":"13","author":"Dubey","year":"2017","journal-title":"Hum Vaccin Immunother."},{"key":"B56","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","article-title":"Children\u2019s oncology group phase 1 study. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children\u2019s oncology group phase 1 study.","volume":"104","author":"Champagne","year":"2004","journal-title":"Blood."},{"key":"B57","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17512433.2018.1398644","article-title":"Pharmacology and pharmacokinetics of imatinib in pediatric patients.","volume":"11","author":"Suttorp","year":"2018","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B58","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1128\/CDLI.6.2.178-180.1999","article-title":"Timing of Development of measles-specific immunoglobulin M and G after primary measles vaccination.","volume":"6","author":"Helfand","year":"1999","journal-title":"Clin Diagn Lab Immunol."},{"key":"B59","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/pbc.24521","article-title":"Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase.","volume":"61","author":"Millot","year":"2014","journal-title":"Pediatr Blood Cancer."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00628\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T09:17:25Z","timestamp":1615281445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00628\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":59,"alternative-id":["10.3389\/fimmu.2020.00628"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00628","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,17]]},"article-number":"628"}}